Jupiter Life Line Hospital
Jupiter Life Line Hospital
Healthcare ServicesKey Fundamentals
MicrocapHospitalsHealthcare ServicesTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has delivered good profit growth of 143% CAGR over last 5 years
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 44d agoJupiter Life Line Hospitals Ltd is a western-India focused hospital chain with a market cap of ₹10,792 crore, trading at a PE of 56.1x. FY26 consolidated revenue grew 15.2% YoY to ₹1,500 crore with EBITDA of ₹343 crore (22.9% margin), while full-year PAT was essentially flat at ₹194 crore. The company is in an aggressive expansion phase, targeting 2,500 beds by FY28-29 from its current base.
- Strong 5-year profit CAGR of 143%, reflecting a significant earnings ramp-up from a low base as the hospital network matured
- FY26 revenue grew 15.2% YoY to ₹1,500 crore, demonstrating consistent top-line momentum even as new capacity ramps up
- ARPOB (Average Revenue Per Occupied Bed) grew 11.7% YoY to ₹67,700 in Q4 FY26, indicating improving case mix and pricing power
- Clear bed expansion visibility from ~1,060 operational beds to 2,500 beds by FY28-29 across MMR, Pune, and Indore — a potential doubling of capacity
- Dombivli greenfield hospital commissioned ahead of schedule and on budget, demonstrating execution capability on capital projects
- Company remains cash-positive and is funding growth through internal accruals with capped debt, reducing dilution risk
- 3-year compounded sales CAGR of 19% and 3-year profit CAGR of 37% show sustained growth trajectory beyond one-off gains
- Q4 FY26 quarterly revenue hit ₹388 crore (up 15.1% YoY) with Q4 PAT rising 12.7% to ₹50.6 crore, showing sequential improvement
- PE ratio of 56.1x is expensive relative to the healthcare sector median, leaving limited margin of safety if growth slows
- Stock trades at 7.06x book value, a steep premium that prices in significant future execution on expansion plans
- Full-year FY26 PAT was nearly flat at ₹194 crore vs ₹194 crore in FY25 (TTM profit growth of -1%), showing earnings stagnation despite revenue growth
- EBITDA margin dipped to 22.9% in FY26 from higher levels, pressured by new hospital ramp-up costs and rising employee expenses (up 11% YoY in Q3)
- Bed occupancy at 61.2% for the three established hospitals suggests room to fill before new capacity additions become earnings-accretive
- Expansion concentrated in western India (MMR, Pune, Indore) creates geographic concentration risk with limited diversification
- Higher depreciation and finance costs from expansion capex compressed Q1 FY26 PAT by 1.6% YoY even as EBITDA grew 19.6%, a trend likely to persist
- Dividend yield of just 0.3% offers negligible income return, making the stock entirely dependent on capital appreciation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 42d ago- Net profit falls 14% in Q1 Aug 1
Net profit declined 14.4% to ₹375.12 million in Q1FY27 despite revenue growth, driven by rising operational and finance costs.
- Revenue surges 16.4% in Q1 Aug 1
Q1FY27 revenue grew 16.4% to ₹4,109.83 million, indicating strong top-line momentum and demand for hospital services.
- Sulcus acquisition completed Aug 1
Completed acquisition of Sulcus Private Limited for ₹3.78 crore, expanding the company's footprint.
- New CFO appointed Aug 1
Harshad Purani appointed as CFO, strengthening the leadership team.
- 24th AGM held, resolutions approved Jul 17
Jupiter Life Line Hospitals held its 24th AGM on July 17, 2026, approving financial statements and key resolutions.
TL;DR: Jupiter Life Line Hospitals is growing revenue at a healthy 16.4% clip and actively expanding via acquisitions, but profitability is under pressure with net profit declining 14.4% due to rising operational and finance costs. The top-line trajectory is encouraging, though margin compression remains a near-term risk to monitor. If cost pressures ease or get absorbed through scale, earnings growth could re-accelerate in coming quarters.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 243 | 263 | 273 | 291 | 289 | 335 | 333 | 337 | 353 | 394 | 365 | 388 | 411 |
| Expenses | 190 | 202 | 211 | 228 | 223 | 257 | 256 | 257 | 275 | 301 | 282 | 299 | 332 |
| Operating Profit | 53 | 61 | 62 | 63 | 65 | 78 | 76 | 80 | 78 | 92 | 83 | 89 | 79 |
| OPM % | 22% | 23% | 23% | 22% | 23% | 23% | 23% | 24% | 22% | 23% | 23% | 23% | 19% |
| Other Income | 4 | 3 | 8 | 10 | 7 | 7 | 7 | 7 | 13 | 11 | 3 | 11 | 11 |
| Interest | 12 | 12 | 1 | 1 | 1 | 1 | 3 | 6 | 8 | 8 | 8 | 9 | 13 |
| Depreciation | 11 | 11 | 11 | 10 | 11 | 14 | 14 | 18 | 21 | 21 | 22 | 23 | 26 |
| PBT | 34 | 41 | 58 | 62 | 60 | 70 | 67 | 63 | 62 | 74 | 57 | 68 | 51 |
| Tax % | -60% | 19% | 25% | 27% | 26% | 26% | 22% | 28% | 29% | 23% | 25% | 26% | 26% |
| Net Profit | 54 | 34 | 44 | 45 | 45 | 52 | 52 | 45 | 44 | 57 | 42 | 50 | 38 |
| EPS in Rs | 1.91 | 1.03 | 1.33 | 1.37 | 1.36 | 1.58 | 1.59 | 1.38 | 1.34 | 1.75 | 1.3 | 1.53 | 1.14 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 463 | 486 | 733 | 893 | 1,073 | 1,302 | 1,500 | 1,558 |
| Expenses | 379 | 419 | 580 | 691 | 831 | 999 | 1,156 | 1,214 |
| Operating Profit | 84 | 67 | 153 | 201 | 242 | 303 | 343 | 344 |
| OPM % | 18% | 14% | 21% | 23% | 23% | 23% | 23% | 22% |
| Other Income | 0 | 4 | 4 | 8 | 22 | 25 | 37 | 35 |
| Interest | 26 | 39 | 44 | 42 | 26 | 11 | 33 | 37 |
| Depreciation | 26 | 31 | 36 | 39 | 42 | 57 | 88 | 93 |
| PBT | 33 | 2 | 77 | 129 | 195 | 261 | 260 | 249 |
| Tax % | 10% | 248% | 34% | 43% | 10% | 26% | 25% | — |
| Net Profit | 30 | -2 | 51 | 73 | 177 | 194 | 194 | 188 |
| EPS in Rs | 1.17 | -0.09 | 2.01 | 2.58 | 5.39 | 5.89 | 5.92 | 5.72 |
| Div. Payout % | 0% | 0% | 0% | 0% | 4% | 3% | 3% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 51 | 51 | 57 | 66 | 66 | 66 |
| Reserves | 186 | 188 | 243 | 309 | 1,103 | 1,291 | 1,479 |
| Borrowings | 272 | 426 | 495 | 469 | 0 | 393 | 584 |
| Other Liabilities | 94 | 124 | 120 | 151 | 112 | 168 | 235 |
| Total Liabilities | 603 | 789 | 909 | 986 | 1,281 | 1,917 | 2,363 |
| Fixed Assets | 435 | 630 | 684 | 720 | 718 | 978 | 1,384 |
| CWIP | 10 | 26 | 27 | 29 | 74 | 185 | 129 |
| Investments | 2 | 7 | 3 | 2 | 17 | 507 | 486 |
| Other Assets | 156 | 126 | 195 | 235 | 473 | 247 | 364 |
| Total Assets | 603 | 789 | 909 | 986 | 1,281 | 1,917 | 2,363 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 74 | 123 | 137 | 176 | 115 | 267 | 268 |
| Investing | -43 | -295 | -84 | -94 | -246 | -497 | -442 |
| Financing | -32 | 184 | 32 | -51 | 128 | 297 | 136 |
| Net Cash Flow | -1 | 12 | 85 | 31 | -3 | 66 | -38 |
| Free Cash Flow | 46 | -118 | 46 | 100 | 29 | -60 | -234 |
| CFO/OP | 106 | 198 | 95 | 97 | 68 | 109 | 97 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 16 | 14 | 19 | 19 | 12 | 18 |
| Inventory Days | 64 | 48 | 39 | 44 | 41 | 38 | 49 |
| Days Payable | 268 | 217 | 157 | 164 | 120 | 99 | 121 |
| Cash Conversion Cycle | -169 | -152 | -104 | -101 | -59 | -49 | -54 |
| Working Capital Days | 17 | -7 | -24 | -24 | -5 | -19 | -21 |
| ROCE % | — | 7% | 17% | 21% | 22% | 18% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jupiter Life Line Hospital insights
62 extracted metrics + investor summaries across FY19–FY27.
Documents
Frequently Asked Questions about Jupiter Life Line Hospital
What does Jupiter Life Line Hospitals Ltd do?
Where is Jupiter Life Line Hospitals Ltd (JLHL) listed?
Which sector does Jupiter Life Line Hospitals Ltd belong to?
What is the market capitalisation of Jupiter Life Line Hospitals Ltd?
What is the PE ratio of Jupiter Life Line Hospitals Ltd?
What is the 52-week high and low of Jupiter Life Line Hospitals Ltd?
Does Jupiter Life Line Hospitals Ltd pay dividends?
What is the Return on Equity (ROE) of Jupiter Life Line Hospitals Ltd?
Company Information
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JLHL.md for Jupiter Life Line Hospitals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.